Ardmore Shipping Corporation
ASC
Cena:
$ 18.83
-0.46 (-2.38%)
Valuace
50
Růst
55
Zdraví
78
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
ARDMORE SHIPPING CORPORATION ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2025
12-02-2026
HAMILTON, BERMUDA, FEB. 12, 2026 /PRNEWSWIRE/ -- ARDMORE SHIPPING CORPORATION (NYSE: ASC) ("ARDMORE"...
Více zde
ASCLETIS SELECTS ORAL AMYLIN RECEPTOR PEPTIDE AGONIST, ASC36, FOR CLINICAL DEVELOPMENT
10-02-2026
- UTILIZING ASCLETIS' PEPTIDE ORAL TRANSPORT ENHANCEMENT TECHNOLOGY (POTENT), ASC36 ORAL TABLETS...
Více zde
SAGIMET ANNOUNCES POSITIVE 52-WEEK DATA FROM LICENSE PARTNER ASCLETIS' OPEN-LABEL PHASE 3 CLINICAL TRIAL EVALUATING THE LONG-TERM SAFETY OF ASC40 (DENIFANSTAT) TABLETS IN PATIENTS WITH MODERATE TO SEVERE ACNE
02-02-2026
SAN MATEO, CALIF., FEB. 02, 2026 (GLOBE NEWSWIRE) -- SAGIMET BIOSCIENCES INC. (NASDAQ: SGMT), A CLIN...
Více zde
ARDMORE SHIPPING ANNOUNCES 2026 INVESTOR DAY IN NEW YORK
29-01-2026
THE COMPANY WILL PRESENT AN OVERVIEW OF ITS STRATEGY AND CAPITAL ALLOCATION FRAMEWORK, ALONG WITH AN...
Více zde
ASCLETIS ANNOUNCES POSITIVE TOPLINE RESULTS FROM ITS PHASE III OPEN-LABEL STUDY OF DENIFANSTAT (ASC40), A FIRST-IN-CLASS, ONCE-DAILY ORAL FASN INHIBITOR FOR ACNE
29-01-2026
- DENIFANSTAT (ASC40), A ONCE-DAILY ORAL FATTY ACID SYNTHASE (FASN) INHIBITOR, DEMONSTRATED FAVOR...
Více zde
ASCLETIS ANNOUNCES FIRST PARTICIPANTS DOSED IN A 13-WEEK U.S. PHASE II STUDY WITH ASC30, AN ORAL SMALL MOLECULE GLP-1R AGONIST FOR THE TREATMENT OF DIABETES
25-01-2026
- TOPLINE DATA FROM THE PHASE II STUDY FOR THE TREATMENT OF DIABETES ARE EXPECTED IN THE THIRD QUA...
Více zde
ASCLETIS ANNOUNCES POSITIVE TOPLINE RESULTS FROM U.S. PHASE I STUDY OF ASC50, A POTENTIAL BEST-IN-CLASS ORAL SMALL MOLECULE IL-17 INHIBITOR
15-12-2025
- THE ELIMINATION HALF-LIFE OF ASC50 AFTER A SINGLE ORAL DOSE WAS 43, 89, 91, 87, 104, AND 85 HOUR...
Více zde
ASCLETIS ANNOUNCES CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTANCE OF NEW DRUG APPLICATION FOR DENIFANSTAT (ASC40), A FIRST-IN-CLASS FASN INHIBITOR FOR ACNE TREATMENT
10-12-2025
-DENIFANSTAT (ASC40) MET ALL PRIMARY, KEY SECONDARY AND SECONDARY EFFICACY ENDPOINTS (ITT ANALYSIS) ...
Více zde
ASCLETIS ANNOUNCES CO-FORMULATION OF ASC36, ONCE-MONTHLY NEXT-GENERATION AMYLIN RECEPTOR AGONIST AND ASC35, ONCE-MONTHLY NEXT-GENERATION GLP-1R/GIPR DUAL AGONIST FOR CLINICAL DEVELOPMENT
12-11-2025
- USING ASCLET I S' PROPRIETARY U LTRA- L ONG- A CTING P LATFORM TECHNOLOGY, CO-FORMULATION OF ASC...
Více zde
ARDMORE SHIPPING CORPORATION ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025
05-11-2025
HAMILTON, BERMUDA , NOV. 5, 2025 /PRNEWSWIRE/ -- ARDMORE SHIPPING CORPORATION (NYSE: ASC) ("ARDMORE"...
Více zde
ASCLETIS PRESENTS FULL ANALYSIS OF PHASE IB STUDY OF ASC30 ORAL TABLET, PHASE IB STUDY OF ASC30 INJECTION, AND PRECLINICAL STUDY OF COMBINATION OF ASC31 AND ASC47 AT OBESITYWEEK® 2025
04-11-2025
-POSITIVE DATA FROM PHASE IB STUDY OF ASC30 ORAL TABLET DEMONSTRATED UP TO 6.5% PLACEBO-ADJUSTED MEA...
Více zde
ASCLETIS SELECTS A BEST-IN-CLASS ONCE-MONTHLY SUBCUTANEOUSLY ADMINISTERED AMYLIN RECEPTOR AGONIST, ASC36, FOR CLINICAL DEVELOPMENT
29-10-2025
-IN HEAD-TO-HEAD NON-HUMAN PRIMATE (NHP) STUDIES, AVERAGE OBSERVED HALF-LIFE OF ASC36 WAS APPROXIMAT...
Více zde
DULY HEALTH AND CARE EXPANDS OUTPATIENT SURGERY ACCESS THROUGH MINORITY SHARE ACQUISITION OF VALLEY ASC IN PARTNERSHIP WITH SURGERY PARTNERS
28-10-2025
DOWNERS GROVE, ILL.--(BUSINESS WIRE)--DULY HEALTH AND CARE, THROUGH ITS CHICAGOLAND MEDICAL GROUP, D...
Více zde
ASCLETIS TO PRESENT STUDY RESULTS OF ASC30 ORAL TABLET, ASC30 INJECTION, AND COMBINATION OF ASC31 AND ASC47 AT OBESITYWEEK® 2025
27-10-2025
-MULTIPLE POSTERS BEING PRESENTED ON ASCLETIS' SMALL MOLECULE AND PEPTIDE OBESITY PROGRAMS -FULL ANA...
Více zde
ARDMORE SHIPPING ANNOUNCES THIRD QUARTER 2025 CONFERENCE CALL AND WEBCAST
22-10-2025
HAMILTON, BERMUDA , OCT. 22, 2025 /PRNEWSWIRE/ -- ARDMORE SHIPPING CORPORATION (NYSE: ASC) ("ARDMORE...
Více zde
ASCLETIS COMPLETES DENIFANSTAT (ASC40) PRE-NDA CONSULTATION WITH CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION
14-10-2025
- DENIFANSTAT (ASC40) MET ALL PRIMARY, KEY SECONDARY AND SECONDARY EFFICACY ENDPOINTS (ITT ANALYSIS)...
Více zde
TKCM IS ENTERING THE 700 BILLION DOLLAR AFFORDABLE HOUSING MARKET
30-09-2025
ASC GLOBAL INC. IS OFFERING NEW SOLUTION TO THE AFFORDABLE HOUSING CRISIS IN THE U.S. BRADENTON, FL ...
Více zde
APOLLO ANNOUNCES LAUNCH OF APOLLO SPORTS CAPITAL
29-09-2025
ASC NAMES AL TYLIS AS CEO, APOLLO PARTNERS ROB GIVONE AND LEE SOLOMON AS CO-PORTFOLIO MANAGERS, AND ...
Více zde
ASCLETIS ANNOUNCES ASC47 IN COMBINATION WITH SEMAGLUTIDE DEMONSTRATED UP TO 56.2% GREATER RELATIVE REDUCTION IN BODY WEIGHT IN PARTICIPANTS WITH OBESITY COMPARED TO SEMAGLUTIDE MONOTHERAPY
21-09-2025
- THE G ASTROINTESTINAL ( GI ) TOLERABILITY OF ASC47 IN COMBINATION WITH SEMAGLUTI...
Více zde
ASCLETIS PRESENTED PHASE III STUDY RESULTS OF FIRST-IN-CLASS FASN INHIBITOR DENIFANSTAT (ASC40) FOR ACNE TREATMENT IN THE LATE BREAKING NEWS SESSIONS OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (EADV) CONGRESS 2025
17-09-2025
--DENIFANSTAT (ASC40) MET ALL PRIMARY, KEY SECONDARY AND SECONDARY EFFICACY ENDPOINTS (ITT ANALYSIS)...
Více zde
ASCLETIS ANNOUNCES FAVORABLE AND DIFFERENTIATED PHARMACOKINETIC PROFILE OF ASC30 ORAL ONCE-DAILY TABLET IN ITS U.S. PHASE IB MULTIPLE ASCENDING DOSE STUDY
27-08-2025
- ASC30 ORAL ONCE-DAILY TABLET DEMONSTRATED APPROXIMATELY 2.3- FOLD TO 3.3-FOLD ...
Více zde
ASCLETIS ANNOUNCES THE COMBINATION OF ASC47 AND ASC31, ITS DUAL GLP-1R/GIPR PEPTIDE AGONIST, DEMONSTRATED SIGNIFICANTLY GREATER WEIGHT LOSS COMPARED TO THE COMBINATION OF ASC47 AND TIRZEPATIDE IN AN ANIMAL MODEL OF OBESITY
17-08-2025
- COMBINATION OF A LOW DOSE OF ASC47 WITH ASC31, A NOVEL PEPTIDE AGONIST TARGETING BOTH GLP-1 RECE...
Více zde
ASCLETIS ANNOUNCES ASC47, A MUSCLE-PRESERVING WEIGHT LOSS DRUG CANDIDATE FOR TREATMENT OF OBESITY, DEMONSTRATED GREATER EFFICACY WITH TIRZEPATIDE THAN SEMAGLUTIDE IN A PRECLINICAL MODEL
12-08-2025
- THE COMBINATION OF ASC47 LOW DOSE WITH TIRZEPATIDE IN DIET-INDUCED OBESE (DIO) MICE R...
Více zde
ARDMORE SHIPPING CORPORATION ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025
30-07-2025
HAMILTON, BERMUDA , JULY 30, 2025 /PRNEWSWIRE/ -- ARDMORE SHIPPING CORPORATION (NYSE: ASC) ("ARDMORE...
Více zde
ARDMORE SHIPPING ANNOUNCES SECOND QUARTER 2025 CONFERENCE CALL AND WEBCAST
16-07-2025
HAMILTON, BERMUDA , JULY 16, 2025 /PRNEWSWIRE/ -- ARDMORE SHIPPING CORPORATION (NYSE: ASC) ("ARDMORE...
Více zde
ASCLETIS ANNOUNCES FIRST PARTICIPANTS DOSED IN U.S. PHASE I CLINICAL STUDY OF ASC50, A POTENTIAL BEST-IN-CLASS ORAL SMALL MOLECULE IL-17 INHIBITOR FOR THE TREATMENT OF PSORIASIS
17-06-2025
- T HE PHASE I TRIAL EVALUATES THE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF ASC50 FOR THE ...
Více zde
ASCLETIS ANNOUNCES POSTER PRESENTATIONS ON THE STUDY RESULTS OF ASC30 AND ASC47 AT THE 85TH SCIENTIFIC SESSIONS OF AMERICAN DIABETES ASSOCIATION (ADA)
08-06-2025
HONG KONG , JUNE 8, 2025 /PRNEWSWIRE/ -- ASCLETIS PHARMA INC. (HKEX: 1672, "ASCLETIS") ANNOUNCES THA...
Více zde
ASCLETIS ANNOUNCES PHASE III TRIAL OF DENIFANSTAT (ASC40), A FIRST-IN-CLASS, ONCE-DAILY ORAL FASN INHIBITOR FOR ACNE, MEETS ALL ENDPOINTS
03-06-2025
DENIFANSTAT (ASC40), A ONCE-DAILY ORAL FATTY ACID SYNTHASE (FASN) INHIBITOR, DEMONSTRATED STATISTICA...
Více zde
APOZ PROJECT PRESENTED AT ITC CONFERENCE
27-05-2025
ASIA PACIFIC OPPORTUNITY ZONE PROJECT WAS PRESENTED TO HOUSTON MAYOR JOHN WHITMIRE AT INTERNATIONAL ...
Více zde
ASCLETIS ANNOUNCES U.S. FDA CLEARANCE OF IND APPLICATION FOR ITS ORAL SMALL MOLECULE IL-17 INHIBITOR, ASC50, FOR THE TREATMENT OF PSORIASIS
22-05-2025
-- ASC50 IS AN IN-HOUSE DISCOVERED AND DEVELOPED ORAL SMALL MOLECULE INTERLEUKIN-17 (IL-17) INHIBITO...
Více zde
Dokumenty nejsou k dispozici
